D4T: Keep it or abandon it?

Asian Biomedicine

Volumn 4, Issue 4, 2010, Pages 541-546

  Hill, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Dose reduction; Resource limited setting; Stavudine

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

BODY WEIGHT; CLINICAL TRIAL; DRUG COST; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECONOMIC ASPECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPODYSTROPHY; LOW DRUG DOSE; PERIPHERAL NEUROPATHY; REVIEW; WORLD HEALTH ORGANIZATION;

EID: 77957961227     PISSN: 19057415     EISSN: None     Source Type: Journal    
DOI: 10.2478/abm-2010-0068     Document Type: Review

References (22)

1. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L, M decins Sans Frontieres. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006; 20:1163-9.
2. Ferradini L, Jeannin A, Pinogues L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up highly active antiretroviral therapy in the district of Malawi: an effectiveness assessment. Lancet. 2006; 367: 1335-42.
3. Gallant J, Staszewski S, Pozniak A, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of Tenofovir DF vs Stavudine in combination therapy in antiretroviral na ve patients. JAMA. 2004; 292:191-201.
4. Stavudine US prescribing information. Bristol Myers Squibb. Available at: www.zerit.com. Accessed November 2006.
5. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007; 8:1-10.
6. World Health Organisation. Addendum to 2006 HIV Treatment Guidelines. Available at: http://www.who.int/ hiv/art/ARTadultsaddendum.pdf. Accessed October 2009.
7. Ruxrungtham K, Kroon E, Ungsedhapand C, Teeratakulpisarn S, Ubolyam S, Buranapraditkun S, et al. A randomised, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-na ve, HIV-infected Thai patients. AIDS. 2000; 14:1375-82.
8. Siangphoe U, Srikaew S, Waiwavaravuth C, Chariyasetphong T, Kamsaw O, Klinbua V, et al. Efficacy and safety of half dose compared to full dose stavudine (d4T) and zidovudine (AZT) in combination with didanosine (ddI) in Thai HIV-infected patients: 96-week results of ACTT002/ARV065 study. Presented at World AIDS Conference, Bangkok, July 2004 [abstr WePeB5952].
9. Ribera E, Paradinero J, Domingo P, Sauleda S, Luque S, Garcia-Arumi E, et al. A randomized study comparing the efficacy and tolerability of low-dose versus standard-dose stavudine in antiretroviral-na ve patients (ETOX study). Presented at 3rd International Conference on AIDS Pathogenesis, Rio de Janiero, Brazil, July 2005 [abstr TuPe2.4c10].
10. UNAIDS, WHO, UNICEF: Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Update 2009. Available on-line at http:// www.who.int/hiv/pub/tuapr-2009-en.pdf. Accessed October 2009.
11. Medecins Sans Frontieres. Untangling the Web of Antiretroviral Price Reductions: A pricing guide for the purchase of ARVs for developing countries. Upcoming 12th Edition-Pre-publication price analysis-July 2009. 1) Available at: http://www.msfaccess.org/ fileadmin/user-upload/diseases/hiv-aids Untangling-the-Web/UntanglingtheWeb12-prepublication-priceanalysis-July09pdf. pdf. Accessed October 2009.
12. Browne M, Mayer K, Chafee S, Dudley MN, Posner MR, Steinberg SM, et al. 2', 3'-didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex. J Inf Dis. 1993, 167: 21-9.
13. Petersen E, Ramirez-Ronda C, Hardy D, Schwartz R, Sacks HS, Follansbee S, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Inf Dis. 1995; 171 (Suppl 1): S 131-9.
14. Spruance S, Pavia A, Mellors J, Murphy R, Gathe J, Stool E, et al. Clinical Efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine experienced patients in a randomized, double-blind, controlled trial. Bristol-Myers Stavudine 019 Study Group. Ann Intern Med. 1997; 126: 355-63.
15. Anderson R, Dunkle L, Smaldone L, Adler M, Wirtz C, Kriesel D, et al. Design and implementation of the stavudine parallel track programme. Comparison of safety and efficacy of two doses of stavudine in a simple trial in the US parallel track programme. J Inf Dis. 1995; 171:118-22.
16. Sanchez-Conde M, de Mendoza C, Jimenez-Nacher I, Barriero P, Gonzalenz-Lahoz J, Soriano V. Reductions in stavudine dosage might ameliorate mitochondrial-associated complications without compromising antiviral activity. HIV Clin Trials. 2005; 6:197-202.
17. Milinkovic A, Martinez E, Lopez S, de Lazzari E, Miro O, Blanco J, et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther. 2007; 12:407-12.
18. Ait Mohand H, Bonmarchand M, Guiget M, Slama L, Slama L, Marguet F, Behin A, et al. Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med. 2008; 9:738-46.
19. Hostede H, Koopmans P, Burger D. Stavudine plasma concentrations and lipoatrophy. J Antimicrob Ag Chemother. 2008; 61:933-8.
20. Clinton HIV-AIDS Initiative. Antiretroviral price list 2009. Available at: http://www.clintonfoundation.org/ files/chaiarvpricelistaugust2009english. pdf. Accessed October 2009.
21. Koegl C, Wolf E, Postel N, Ruemmelein N, Postel N, Jaegel-Guedes E, et al. Low dose stavudine: as effective as standard dose but less side effects. Presented at 9th European AIDS Conference (EACS), Warsaw, October 25 2003. [abstract 9.8/5].
22. Hanvanich M, Prasanthai V, Riengchan P, Arunyingmongkol K, Intalapaporn P, Hiransuthikul N, et al. Reduction of d4T dosage improves lipoatrophy without virologic failure. Antiviral Therapy. 2003; 8 (Suppl 1): S392.